AVXL · Anavex Life Sciences Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $37.59M | $41.84M | $43.72M | $37.92M | $32.98M | $25.23M |
| SG&A | $11.04M | $11.04M | $12.04M | $13.07M | $9.02M | $5.86M |
| Total Operating Expenses | $51.41M | $52.88M | $55.76M | ($50.99M) | $42.00M | $31.09M |
| D&A | - | - | - | - | - | - |
| Operating Income | ($51.41M) | ($52.88M) | ($55.76M) | ($31.09M) | ($37.64M) | ($26.26M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($46.38M) | ($43.00M) | ($47.51M) | ($47.98M) | ($37.91M) | ($26.28M) |
| EPS - Basic | ($0.54) | ($0.52) | ($0.54) | - | - | - |
| EPS - Diluted | ($0.54) | ($0.52) | ($0.54) | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $102.58M | $132.19M | $151.02M | $149.16M | $152.11M | $29.25M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $4.25M | $9.63M | $4.32M | $3.82M | $4.74M | $3.99M |
| Current Assets | - | - | - | - | - | - |
| Total Assets | $103.81M | $135.57M | $154.39M | $152.70M | $161.62M | $34.54M |
| Current Liabilities | - | - | - | - | - | - |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $8.95M | $15.30M | $12.53M | $10.21M | $10.80M | $5.04M |
| Stockholders' Equity | $94.87M | $120.26M | $141.85M | $142.49M | $150.82M | $27.24M |
| Retained Earnings | ($382.45M) | ($336.07M) | ($293.07M) | ($245.56M) | ($197.59M) | ($159.68M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($39.04M) | ($30.81M) | ($27.79M) | ($24.24M) | ($30.38M) | ($21.29M) |
| Investing Cash Flow | - | - | - | - | - | - |
| Financing Cash Flow | $9.43M | $11.97M | $29.65M | $21.29M | $153.24M | $28.35M |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -44.7% | -31.7% | -30.8% | -31.4% | -23.5% | -76.1% |
| Return on equity | -48.9% | -35.8% | -33.5% | -33.7% | -25.1% | -96.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | - | - | - | - | - | - |
| Quick ratio | - | - | - | - | - | - |
| Cash ratio | - | - | - | - | - | - |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.09 | 1.13 | 1.09 | 1.07 | 1.07 | 1.27 |
| Liabilities / Assets | 0.09 | 0.11 | 0.08 | 0.07 | 0.07 | 0.15 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 8.0x | 3.9x | 3.2x | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 2.8% | 5.2% | -79.3% | 17.4% | -43.4% | -52.8% |
| Net income growth (YoY) | -7.8% | 9.5% | 1.0% | -26.6% | -44.2% | 0.1% |
| EPS growth (YoY) | -3.8% | 3.7% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -21.1% | -15.2% | -0.4% | -5.5% | 453.7% | 34.2% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- -Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing ANAVEX LIFE SCIENCES CORP. against the 5 most active filers in the same SIC group.